S
BBIO icon

SignatureFD’s BridgeBio Pharma BBIO Stock Holding History

SignatureFD’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.3K Sell
676
-5
-0.7% -$350 ﹤0.01% 1876
2026
Q1 		$50.6K Buy
681
+10
+1% +$725 ﹤0.01% 1711
2025
Q4 		$51.3K Buy
671
+9
+1% +$591 ﹤0.01% 1636
2025
Q3 		$34.4K Hold
662
– – ﹤0.01% 1845
2025
Q2 		$28.6K Buy
662
+21
+3% +$764 ﹤0.01% 1888
2025
Q1 		$22.2K Buy
641
+488
+319% +$16.5K ﹤0.01% 2012
2024
Q4 		$4.2K Buy
153
+11
+8% +$284 ﹤0.01% 2659
2024
Q3 		$3.62K Sell
142
-7
-5% -$184 ﹤0.01% 2664
2024
Q2 		$3.77K Sell
149
-57
-28% -$1.56K ﹤0.01% 2607
2024
Q1 		$6.37K Sell
206
-8
-4% -$272 ﹤0.01% 2471
2023
Q4 		$8.64K Buy
214
+14
+7% +$420 ﹤0.01% 2323
2023
Q3 		$5.27K Sell
200
-14
-7% -$397 ﹤0.01% 2469
2023
Q2 		$3.68K Buy
214
+72
+51% +$1.08K ﹤0.01% 2617
2023
Q1 		$2.35K Buy
142
+35
+33% +$408 ﹤0.01% 2754
2022
Q4 		$815 Sell
107
-33
-24% -$316 ﹤0.01% 3015
2022
Q3 		$1K Buy
140
+92
+192% +$956 ﹤0.01% 2911
2022
Q2 		$0 Sell
48
-1,253
-96% -$10.5K ﹤0.01% 3111
2022
Q1 		$13K Buy
+1,301
New +$13.4K ﹤0.01% 2030

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

SignatureFD's BBIO Position: Q2 2026 in Review

SignatureFD reduced its BridgeBio Pharma (BBIO) stake by 0.73% in Q2 2026, selling an estimated $350 and leaving 676 shares worth $50.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

SignatureFD first reported a position in BBIO in Q1 2022 and has held it in 18 quarters since. The position peaked at $51.3K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • SignatureFD held 676 shares of BridgeBio Pharma worth $50.3K as of Q2 2026.
  • SignatureFD sold 5 BridgeBio Pharma shares in Q2 2026, an estimated $350.
  • BridgeBio Pharma made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1876 holding.
  • SignatureFD first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 18 quarters since.
  • SignatureFD's BridgeBio Pharma position peaked at $51.3K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.